CENTOGENE

The Essential Life Science Partner for Data-Driven Answers in Rare & Neurodegenerative Diseases

CENTOGENE (CNTG) Company Presentation
January 2023

Disclaimer

This presentation has been prepared by CENTOGENE N.V. (the "Company"), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and neither the delivery of this presentation at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation contains statements that constitute "forward-looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of our strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology, such as "anticipate," "intend," "believe," "estimate," "plan," "seek," "project" or "expect," "may," "will," "would," "could" or "should," the negative of these terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions and on information currently available to the Company. However, these forward-looking statements are not a guarantee of our performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, such as negative economic and geopolitical conditions and instability and volatility in the worldwide financial markets, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth and enter into new client relationships, our dependency on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Company's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The Company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company's own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the Company believes its own internal research is reliable, such research has not been verified by any independent source.

For further information, please refer to the Risk Factors section in our Annual Report for the year ended December 31, 2021, on Form 20-F filed with the SEC on March 31, 2022, and other current reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

CENTOGENE @ a glance

- Headquarters **Rostock, Germany**, with locations in **Boston, MA**, **Berlin, Germany**, **Belgrade, Serbia**, and **Rotkreuz, Switzerland**
- ~**420 employees**[1]
- Listed on **Nasdaq** in November 2019 (Ticker: CNTG)

- **FY2021 revenues of €42.3 million**[2]
- Guidance[3] FY2022:
  - **Revenues of ~ €46.5 - €48.2 million** YoY growth 9-13%

- **CENTOGENE Biodatabank**, the **world's largest real-world data repository** for rare and neurodegenerative diseases
- State-of-the-art **genomics and multiomics reference lab** (ISO, CAP, & CLIA certified)

- **>50 collaborations with biotech/biopharma** partners, covering over **46 rare diseases**[4]
- **Market access and expansion**, **clinical development**, **target and drug screening**

1 Based on FTE basis per 2022, excl. consultants, interns, long-term leavers (maternity, sick leave, …). [2] Prior year financials as revised per H1 2022 results filing on Dec 22, 2022 (unaudited and unreviewed). As of Q1 2022, the Company reported COVID-19 testing as discontinued operations. I.e. FY2021 only reflects revenues from the Company's Diagnostics & Pharma segments. The COVID-19 testing business was exited end of Q1 2022. [3] Guidance as communicated per H1 2022 earnings announcement on Dec 22, 2022. [4] Reflecting total, not related to current reporting period only

Essential Life Science Partner for Data-Driven Answers in Rare and Neurodegenerative Diseases



CENTOGENE

- **Highly diverse real-world data repository** for Rare & NeuroD Diseases
- Broadest **diagnostic testing portfolio** for rare diseases
- **Accelerate & de-risk** discovery, development, and commercialization

Insights into 2,500 rare and neurodegenerative diseases to support breakthrough therapies



CENTOGENE

- **Highly diverse real-world data repository** for Rare & NeuroD Diseases
- Broadest **diagnostic testing portfolio** for rare diseases
- **Accelerate & de-risk** discovery, development, and commercialization

The Opportunity: By 2024, 18% of Rx Worldwide Expected to Target Rare Diseases

Significant Need Rare Diseases

- **~350 million people affected** by rare genetic diseases, **~90% undiagnosed**
- Estimated **80%** of ~7,000 rare diseases are **genetic in origin**: ~5,600[1]
- Public datasets are **~80% of European descent**[7]
- <5% of rare diseases have meaningful therapies

Growing Market for Rare Rx

- Rare diseases market expected to **grow 11+% to 2024**[3]
- By 2024, rare disease products expected ~18% ℞ sales[4]
- FDA have approved 23 gene/cell therapies to date[5]
- **>50% of FDA approvals** in 2021 were **orphan drugs**[6]

Stakeholder Pressure to Act

- **Regulatory/payor scrutiny** raises standards for approval, access, and entry
- **Patient engagement** for new RD, NDD, & gene therapies; even with premium priced products
- **Stratification and patient profiling** can improve labelling, pricing optimization and success

1 Compare Centogene 20-F for FY2021 p. 56 I 2 CENTOGENE Biodatabank statistic per Dec 31, 2021. I 3 & 4 EvaluatePharma – Orphan Drug Report 2020 p. 2 I 5 Based on FDA approvals per May 2022. [Approved Cellular and Gene Therapy Products I FDA] I 6 EvaluatePharma – Orphan Drug Report 2022 p. 2 I 7 The Scientist (2019) "Lack of Diversity in Genetic Datasets is Risky for Treating Disease", reflecting distribution of ancestry of individuals in genome-wide association studies (GWAS) as of January 2019 I *Statements reflect internal management estimates.

Near-term opportunities in addressing key stakeholder challenges

Our ambition is to be the essential life science partner for data-driven in rare and neurodegenerative diseases

Fueling revenues, growing CENTOGENE Biodatabank, and building pharma partnerships

3 STRATEGIC PILLARS

1 DIAGNOSTICS

Highly differentiated testing portfolio

Easy logistics via CentoCard & CentoCloud

WES/WGS

Multiomics

Network of ~29,000 active physicians

2 CENTOGENE BIODATABANK

Fuel CENTOGENE Biodatabank with biomaterial, multiomics, as well as clinical data

Productize CENTOGENE Biodatabank (data monetization)

3 BIOPHARMA PARTNERSHIPS

MARKET ACCESS & EXPANSION

Real world Registry

Early Access Programs

Patient Stratification, Genetic & Biomarker Profiling, Modelling

Patient Identification & Diagnostics

CLINICAL DEVELOPMENT

Observational Studies (e.g., epidemiology, patient finding, genetic & biomarker profiling)

POC/ Ph II/III:

Patient Multiomic Profiling, Stratification, Modelling, Efficacy Marker

Patient Identification & Diagnostic

TARGET & DRUG SCREENING

Patient- derived Cell Models & Multiomics

Biomarker/ Assay Identification & Validation

CENTOGENE BIODATA NETWORK (Insight Reports & CNTG Biodatabank licenses)

CENTOGENE Biodatabank: Highly diverse real-world data repository for rare and neurodegenerative diseases



Metrics per July, 2022. Active Physicians defined as contact with CENTOGENE within the last 5 years, respectively.

The breadth and depth of the CENTOGENE Biodatabank makes it a unique resource

~700,000 individuals
>30,000 via clinical studies

>400,000 biosamples from
>120 countries

~30,000 active physicians
in our network

~50% broad research consent
(>70% in recent years)



High diversity in geographies,
ethnicities and
patient characteristics

Country represented in Biodatabank Country not represented in Biodatabank

>70% of individuals of **non-european descent***

>31 million unique variants

High share of pediatric cases
>13k families with trio analysis

>2,500 rare diseases covered
with diagnosed patients

Clinical Diagnostics

Market Access & Expansion

Clin. Development Support

Target & Drug Screening

Metrics per July, 2022. Active defined as contact with CENTOGENE within the last 5 years, respectively. * Internal estimate.

First-in-class data capture and proprietary curation and analysis technologies

Data capture



Gold standard for DNA and multiomic sampling
(from >120 countries)

All common forms of sampling accepted
(incl. buccal swab)

CentoPortal

Clinical data capture

Clinical data extraction & curation

Whole Genome Sequencing

State-of-the-art mass spectrometry

RNA sequencing

Data bioinformatics

CENTOGENE BIODATABANK

Automated pipelines for

- variant annotation
- prioritization
- medical reporting
- > 31 million variants
- multiomic analysis and combination expertise

Data utilization

Clinical Diagnostics

Biopharma Partnerships

Target & Drug Screening

Clinical Development Support

Market Access & Expansion

Value chain supported by advanced bioinformatics and AI tools

CAP ACCREDITED
COLLEGE of AMERICAN PATHOLOGISTS

Diagnostics: A distinctive offering and services that support efficient and timely diagnosis of rare and neurodegenerative diseases, leading to better treatment and health outcomes

Highly differentiated testing portfolio in state-of-the-art CLIA/CAP certified laboratory with **deep medical expertise**

Exome testing



Genome testing



Multiomic testing

Easy logistics for centralized testing enabling **broad access to multiomics**

Dry-lab (SaaS) solution enabling laboratories around the world to deliver leading diagnostic **insights to local patients**

Unique global footprint with **network of ~30,000 active physicians** and **focus on countries with a high prevalence of rare diseases**

CENTOGENE Unique Pharma Offering: Our ambition is to be the essential life science partner for data-driven answers in rare and neurodegenerative diseases

Target & Drug Screening

- Patient-derived Cell Models & Multiomics
- Biomarker/Assay Identification & Validation

Clinical Development

Observational Studies

- Observational Studies (e.g., epidemiology, patient finding, genetic & biomarker profiling)

POC/ Ph II/III

- Patient Multiomic Profiling, Stratification, Modelling, Efficacy Marker
- Patient Identification & Diagnostics

Market Access & Expansion

- RW Registry & Early Access Programs
- Patient Stratification, Genetic & Biomarker Profiling, Modelling
- Patient ID & Diagnostics

CENTOGENE Biodata Network

- Insight Reports (e.g., new and existing reports, clinical, genetic, epidemiology)
- CNTG Biodatabank Licenses

Insilico Medicine · evotec · DENALI THERAPEUTICS · alector · agios · Takeda · Pfizer · PTC THERAPEUTICS

Market Access and Expansion: Maximize access and personalize patient, provider, and pharma value

Market Access and Expansion

- Real world registry
- Early access programs

- Patient Stratification
- Genetic and Biomarker Profiling
- Modelling

- Patient Identification
- Patient Diagnostics

- CENTOGENE Biodata Network
  - Insight Reports & CNTG Biodatabank Licenses

Takeda Shire

- **2015 - Ongoing**
- **Rare metabolic and rare neurodegenerative diseases**
- **Provide diagnostic testing services** to identify patients with **rare metabolic and rare neurodegenerative diseases**
- **42 Countries**

SAREPTA THERAPEUTICS

- **2019 - 2022**
- Duchenne muscular dystrophy (DMD)
- **DMD Sponsored testing program (250 samples)**
- **5 countries:** UAE, KSA, Lebanon, Kuwait, Egypt

Pfizer ATTR:INFORMED

- **2015 - Ongoing**
- **Hereditary transthyretin amyloidosis (hATTR) disease**
- Sponsored testing program with > 600 samples from 10 countries (Europe) & 125 samples (U.S.)

PTC THERAPEUTICS REVEAL-CP™

- **2019 - Ongoing**
- Identify patients in **DMD &** Aromatic L-amino Acid Decarboxylase (**AADC)**
- **Genetic testing** and **biomarker analytics** for AADC deficiency in **65 countries** (LATAM, Europe, MENA)
- >2,500 DMD & >2,900 AADC samples screened

Clinical Development: Accelerate and expand pharma partnerships

Clinical Development

Observational studies

- Epidemiology & Patient finding
- Genetic & biomarker profiling

POC/Ph II/III

- Patient multiomic profiling
- Stratification, Modelling, and Efficacy markers
- Patient identification & diagnostics

CENTOGENE Biodata Network

- Insight Reports & CNTG Biodatabank Licenses

ALEXION AstraZeneca Rare Disease

- **2021**
- **Hypophosphatasia (HPP)**
- Strensiq (innovative enzyme replacement therapy)
- **De novo variant identification** for HPP and **identification of potential new genes** causing HPP
- **Germany**

DENALI THERAPEUTICS

- **2018 - Ongoing** (ROPAD Study with extensions)
- **Parkinson's disease (PD)**
- **Enroll and genotype 12,500 patients**
- **10 countries**
- Recently extended to test 5,000 patients more

Takeda

- **2018 - 2021**
- **Gaucher disease**
- **Longitudinal natural history study** (LysoProof) with **>1,600 samples analyzed**
- **13 countries** (EU, LATAM, APAC, MENA)
- **Identified and genetically tested >250 Gaucher patients**

agios

- **2021 - Ongoing**
- **Pyruvate kinase ("PK") deficiency**
- **Genetic testing and identification of causative mutations**, incl. HBA1, HBA2, and HBB genes, in Ph. II/III trials
- **20 Countries** (North America, Europe, MENA, APAC, & LATAM)

Alnylam PHARMACEUTICALS

- **2020 - Ongoing**
- **Hereditary transthyretin-related amyloidosis (hATTR)**
- **Longitudinal study providing** a **molecular genetic diagnosis of hATTR** via NGS and MLPA
- **Germany**
- **5,000 patients enrolled**

alector

- **2021 - Ongoing**
- Frontotemporal dementia (FTD)
- **Enroll and genetically test over 3,000 FTD patients in EFRONT Study**
- **7 countries** (Belgium, Germany, Greece, Italy, Portugal, Spain, and Turkey)

Target & Drug Screening: Build partnerships around precision and confidence

Target and Drug Screening

Target & Drug Screening

- Patient-derived cell models & multiomics
- Biomarker/Assay identification & validation

CENTOGENE Biodata Network

- Insight Reports & CNTG Biodatabank Licenses

CENTOGENE Insilico Medicine

- **2021 - Ongoing**
- **Niemann-Pick type C**
- **Collaboration to generate data set to enable start of drug discovery**

CENTOGENE evotec

- **2020 - Ongoing**
- **Gaucher Disease – joint drug discovery project**
- **Joint drug discovery project** to identify small molecules reducing **biomarker Lyso-GB1** in disease cell models
- **Transcriptomic** and **metabolomic** data set enabling patient selection with highest unmet need

CENTOGENE

- **2021 - Ongoing**
- **Friedreich's Ataxia, Duchenne Muscular Dystrophy, Hereditary transthyretin-related amyloidosis**
- **Novel biomarker discovery to stratify and monitor patients for disease severity/progression** and to enable the **discovery of disease modifiers** explaining heterogeneity

Pfizer

- **2018 - 2022**
- **Rare neurodegenerative diseases**
- **Data Access and Collaboration Agreement granting access** to the **CENTOGENE Biodatabank** for **discovery & validation of novel genetic and biochemical targets** for the potential development of **new therapies for rare diseases**

CENTOGENE Financials – per H1 2022

Core Business - Dx and Biopharma revenues[1]



Outgrowing the market

Diagnostics

- H1' 22 revenues of 14.5 € million +15% vs H1'21
- # tests for Whole Exome/ Genome Sequencing (WES/ WGS) up 34.7% YoY
- Received CE-mark for CentoCloud decentralized SaaS and clinical decision support platforms

Recovering from COVID impact

Biopharma

- H1' 22 revenues of 6.9 € million +7% vs H1'21
- Increased activity in the clinical studies of pharmaceutical partners
- 45 active collaborations; 12 contracts signed in H1'22; there/of 10 with existing partners
- Launched Biodata Network data-driven partnering solutions for biopharma and research

1. In EUR million, rounded, graph not drawn to scale. Core Business defined as revenue from the Diagnostics and Pharma reporting segments, excludes COVID-19 testing. Prior period financials as revised per H1 2022 results filing on Dec 22, 2022 (unaudited and unreviewed). Guidance as communicated per H1 2022 earnings announcement on Dec 22, 2022, bar chart reflects midpoint

Near- and mid-term priorities

Topline

Growth

- Focus on unique and transformative business model
- Expand pharma partnerships
  - Fully execute on our ongoing partnerships and target ~20+ new pipeline deals
- Keep growing Dx at above-market level
  - Focus on profitable growth
  - Commercial excellence, CentoCloud, & multiomics

2022 Guidance:*

Revenues

~46.5-48.2 €M

+9-13% YoY

Bottomline

Cost management

- Drive fit-for-purpose organization
- Focus on efficient operations and margin improvement

H1 2022

Revenues of €21.4M up +13% yoy driven by Diagnostics +15% yoy and Pharma +7% yoy

Runway

Cashflow

- Sector is not about growth at all costs
- Diligently manage cash and extend runway

$

~$62M financing (~€55M) in Q1 2022: €15M PIPE & $45M secured debt facility **

* Revenues reflect the Diagnostics and Pharma reporting segments, and do not include the COVID-19 Testing revenues recorded in the period 2020 – Q1 2022. COVID-19 Testing has been reported as discontinued operations since Q1 2022. Prior period financials as revised per H1 2022 results filing on Dec 22, 2022 (unaudited and unreviewed). Guidance as communicated per H1 2022 earnings announcement on Dec 22, 2022. ** CENTOGENE announced the closing of a € 15 million (~$ 17 million per USD/EUR Fx rate at that time) private placement financing incl. warrants as well as the entry into a USD 45 million senior secured loan facility on February 1, 2022. / Image source: flaticon.com

CENTOGENE

Thank you